Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Adult-onset Still disease is a rare systemic autoinflammatory disorder characterized by recurrent high fever, arthritis, rash, and multi-organ inflammation. As per Global Autoimmune Institute, its prevalence ranges from 0.73 to 6.77 cases per 100,000 people worldwide. According to the adult onset still disease epidemiology forecast by Expert Market Research, increasing awareness and improved diagnosis are expected to support better disease recognition and management of systemic inflammation.
Base Year
Historical Period
Forecast Period

Read more about this report - Request a Free Sample
Expert Market Research's “Adult Onset Still Disease Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of adult onset still disease. It projects the future incidence and prevalence rates of adult onset still disease cases across various populations. The study covers age, gender, and type as major determinants of the adult onset still disease population. The report highlights patterns in the prevalence of adult onset still disease over time and projects future trends based on multiple variables.
The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of adult onset still disease in the 8 major markets.
Regions Covered
Adult onset still disease (AOSD) is a rare systemic autoinflammatory disorder characterized by recurrent high fever, inflammatory arthritis, an evanescent salmon-colored rash, and elevated inflammatory markers. Although its exact cause remains unknown, the disease is believed to result from abnormal activation of the innate immune system, leading to excessive production of pro-inflammatory cytokines. Adult onset still disease is generally classified into three clinical patterns: monocyclic (single episode), polycyclic (recurrent flares), and chronic articular disease. Early recognition and systemic inflammation assessment are essential to minimize complications and improve long-term outcomes.
|
Parameter |
Insight |
|
Largest Patient Pool |
United States |
|
Fastest Growing Region |
India |
|
High-Risk Population |
Young adults, particularly individuals aged 16–35 years, with a slight female predominance |
|
Key Diagnostic Method |
Clinical evaluation supported by Yamaguchi or Fautrel classification criteria, inflammatory biomarkers, and exclusion of infectious, malignant, and autoimmune disorders |
|
Major Risk Factor |
Dysregulated immune response and excessive pro-inflammatory cytokine production |
|
Major gap in the market |
Delayed diagnosis due to nonspecific symptoms and the absence of disease-specific diagnostic biomarkers |
The adult onset still disease epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the adult onset still disease epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for adult onset still disease and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.
|
Epidemiology Segment |
Key Insights |
|
Diagnosed Prevalent Cases of the Disease |
Adult-onset Still disease (AOSD) is a rare inflammatory disorder with an estimated global prevalence of 0.73–6.77 cases per 100,000 people. As per the Global Autoimmune Institute, improved awareness and diagnosis suggest the disease may be more frequently recognized than previously reported. Based on Sheng Li et al. (2023), another epidemiological estimate reported a prevalence of 3.9 cases per 100,000 individuals. |
|
Gender-Specific Cases of the Disease |
A slight female predominance has been observed in Adult-onset Still disease. According to the Global Autoimmune Institute, females are affected slightly more often than males. As reported by Eleonore de Fritsch et al. (2023), 70.6% of evaluated patients were female, indicating a higher disease burden among women in the studied population. |
|
Age-Specific Cases of the Disease |
Adult-onset Still disease predominantly affects young adults but may occur throughout adulthood. As per Christopher Saleh (2025), the disease demonstrates bimodal age peaks at 15–25 years and 36–46 years. Findings from Sushmita Mittal et al. (2024) similarly identified peaks at 15–25 years and 36–45 years, with increasing recognition among older adults. |
|
Ethnicity-Wise Cases of the Disease |
Disease burden may vary across ethnic populations due to differences in genetic susceptibility, environmental exposure, and healthcare accessibility. As reported by Eleonore de Fritsch et al. (2023), epidemiological evaluation in the Afro-Caribbean population contributes to understanding ethnic variations and supports broader population-based disease surveillance. |
|
Mortality and Survival Analysis of the Disease |
Mortality is generally associated with severe systemic disease and disease-related complications. According to Eleonore de Fritsch et al. (2023), 11.76% of patients died during follow-up, while 9% developed hemophagocytic lymphohistiocytosis, including one fatal case, highlighting the importance of early disease management and long-term monitoring. |
|
Disease Type |
Prevalence |
|
Systemic Pattern |
As reported by Eleonore de Fritsch et al. (2023), the systemic pattern accounted for 78.8% of Adult-onset Still disease cases, representing the predominant clinical subtype and contributing substantially to the overall epidemiological burden. |
|
Chronic Joint Pattern |
The chronic joint pattern represents a recognized subtype characterized by persistent articular involvement and contributes to the long-term disease burden through ongoing disease activity and healthcare utilization. |

Read more about this report - Request a Free Sample
The adult onset still disease epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.
|
Country |
Key Insights |
|
United States |
Findings from Sushmita Mittal et al. (2024) indicate that Adult-onset Still disease has an estimated annual incidence of 0.16–0.40 cases per 100,000 adults in the United States and exhibits a bimodal age distribution with peaks at 15–25 years and 36–45 years. |
|
Germany |
Adult-onset Still disease is recognized as a rare inflammatory disorder in Germany, with epidemiological assessments focusing on disease occurrence, demographic distribution, and healthcare burden within the affected population. |
|
France |
Olfa Frikha et al. (2025) estimated the prevalence of Adult-onset Still disease in France at 0.16–0.40 cases per 100,000 people. Based on Sheng Li et al. (2023), a French survey also found that 18% of patients were older than 55 years at diagnosis, reflecting an increasing proportion of older-onset cases. |
|
Italy |
As per Sheng Li et al. (2023), 16.7% of Adult-onset Still disease patients in Italy experienced disease onset after 60 years of age, demonstrating the growing recognition of elderly-onset disease within the country. |
|
Spain |
Adult-onset Still disease remains an uncommon inflammatory disorder in Spain, where epidemiological evaluations generally focus on disease frequency, demographic characteristics, and healthcare burden across affected populations. |
|
United Kingdom |
The epidemiological studies in the United Kingdom primarily assess disease occurrence, demographic trends, and patterns of healthcare utilization among affected individuals. |
|
Japan |
According to Olfa Frikha et al. (2025), the estimated prevalence of Adult-onset Still disease in Japan is 3.7 cases per 100,000 people. As reported by Sheng Li et al. (2023), 33.1% of patients were older than 60 years in 2021, increasing to 41.9% older than 65 years in 2022, indicating a shift toward older age at disease onset. |
|
India |
Adult-onset Still disease is recognized as a rare inflammatory disorder in India, with epidemiological evaluations emphasizing disease recognition, demographic distribution, and patterns of diagnosis among affected adult populations. |
The regional epidemiology landscape for Adult Onset Still Disease continues to face significant challenges because of limited disease awareness, delayed diagnosis, and the absence of validated disease-specific biomarkers. Many cases remain underrecognized, particularly in emerging healthcare systems, resulting in incomplete epidemiological data and delayed treatment initiation. Increasing physician awareness, expanding access to advanced diagnostic testing, strengthening rare disease registries, and improving surveillance programs present substantial opportunities for more accurate disease burden estimation. Enhanced real-world evidence generation across the United States, Europe, Japan, and India will further support clinical decision-making and healthcare planning.
Treatment for adult onset still disease focuses on controlling inflammation, relieving symptoms, preventing disease progression, and reducing the risk of complications. Mild cases are commonly managed with nonsteroidal anti-inflammatory drugs and corticosteroids, while persistent or severe disease often requires conventional disease-modifying antirheumatic drugs, such as methotrexate. Patients with refractory or systemic manifestations may benefit from biologic therapies targeting interleukin-1 or interleukin-6 pathways, and, in selected cases, tumor necrosis factor inhibitors. Regular cytokine-targeted therapy monitoring and multidisciplinary care are essential to achieve sustained disease remission.
Psoriatic Arthritis Pipeline Analysis Report
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Report Features |
Details |
|
Base Year |
2025 |
|
Historical Period |
2019-2025 |
|
Forecast Period |
2026-2035 |
|
Epidemiology Statistics Provided |
|
|
Segmentation Provided |
|
|
Geographies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.